{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:28:35Z","timestamp":1791505715213,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"STI2030-Major Projects","award":["2022ZD0213800"],"award-info":[{"award-number":["2022ZD0213800"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00259-025-07326-8","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T22:57:41Z","timestamp":1746745061000},"page":"4547-4557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["[68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors"],"prefix":"10.1007","volume":"52","author":[{"given":"Donglang","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunguo","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2667-281X","authenticated-orcid":false,"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"7326_CR1","doi-asserted-by":"publisher","first-page":"108296","DOI":"10.1016\/j.pharmthera.2022.108296","volume":"239","author":"X Liu","year":"2022","unstructured":"Liu X, Deng J, Yuan Y, Chen W, Sun W, Wang Y, et al. Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer. Pharmacol Ther. 2022;239:108296. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108296.","journal-title":"Pharmacol Ther"},{"key":"7326_CR2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00259-023-06454-3","volume":"51","author":"W Huang","year":"2024","unstructured":"Huang W, Liang C, Zhang Y, Zhang D, An S, Wu Q, et al. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers. Eur J Nucl Med Mol Imaging. 2024;51:380\u201394. https:\/\/doi.org\/10.1007\/s00259-023-06454-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7326_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41698-024-00584-z","volume":"8","author":"DD Zhou","year":"2024","unstructured":"Zhou DD, Zhai XT, Zhang LW, Xie ZH, Wang Y, Zhen YS, et al. A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers. NPJ Precis Oncol. 2024;8:94. https:\/\/doi.org\/10.1038\/s41698-024-00584-z.","journal-title":"NPJ Precis Oncol"},{"key":"7326_CR4","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1158\/1078-0432.Ccr-22-1305","volume":"29","author":"JM Sperger","year":"2023","unstructured":"Sperger JM, Helzer KT, Stahlfeld CN, Jiang D, Singh A, Kaufmann KR, et al. Expression and therapeutic targeting of TROP-2 in Treatment-Resistant prostate Cancer. Clin Cancer Res. 2023;29:2324\u201335. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-1305.","journal-title":"Clin Cancer Res"},{"key":"7326_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1158\/1535-7163.Mct-07-2003","volume":"7","author":"J Wang","year":"2008","unstructured":"Wang J, Day R, Dong Y, Weintraub SJ, Michel L. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther. 2008;7:280\u20135. https:\/\/doi.org\/10.1158\/1535-7163.Mct-07-2003.","journal-title":"Mol Cancer Ther"},{"key":"7326_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1472-6890-12-22","volume":"12","author":"E Bignotti","year":"2012","unstructured":"Bignotti E, Zanotti L, Calza S, Falchetti M, Lonardi S, Ravaggi A, et al. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clin Pathol. 2012;12:22. https:\/\/doi.org\/10.1186\/1472-6890-12-22.","journal-title":"BMC Clin Pathol"},{"key":"7326_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.pathol.2016.04.002","volume":"48","author":"A Bychkov","year":"2016","unstructured":"Bychkov A, Sampatanukul P, Shuangshoti S, Keelawat S. TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma. Pathology. 2016;48:425\u201333. https:\/\/doi.org\/10.1016\/j.pathol.2016.04.002.","journal-title":"Pathology"},{"key":"7326_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1369\/0022155411410430","volume":"59","author":"LP Stepan","year":"2011","unstructured":"Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L, Sutherland CL. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochemistry: Official J Histochem Soc. 2011;59:701\u201310. https:\/\/doi.org\/10.1369\/0022155411410430.","journal-title":"J Histochem Cytochemistry: Official J Histochem Soc"},{"key":"7326_CR9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1078-0432.Ccr-23-2566","volume":"30","author":"A Bessede","year":"2024","unstructured":"Bessede A, Peyraud F, Besse B, Cousin S, Cabart M, Chomy F, et al. TROP2 is associated with primary resistance to immune checkpoint Inhibition in patients with advanced Non-Small cell lung Cancer. Clin cancer Research: Official J Am Association Cancer Res. 2024;30:779\u201385. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-2566.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"key":"7326_CR10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.Cd-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint Blockade. Cancer Discov. 2016;6:827\u201337. https:\/\/doi.org\/10.1158\/2159-8290.Cd-15-1545.","journal-title":"Cancer Discov"},{"key":"7326_CR11","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.Ccr-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for Cancer immunotherapies in the era of checkpoint Inhibition. Clin Cancer Res. 2016;22:1865\u201374. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1507.","journal-title":"Clin Cancer Res"},{"key":"7326_CR12","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","volume":"120","author":"W Wei","year":"2020","unstructured":"Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: concept, design, and applications. Chem Rev. 2020;120:3787\u2013851. https:\/\/doi.org\/10.1021\/acs.chemrev.9b00738.","journal-title":"Chem Rev"},{"key":"7326_CR13","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1007\/s00259-021-05211-8","volume":"48","author":"C Eze","year":"2021","unstructured":"Eze C, Schmidt-Hegemann NS, Sawicki LM, Kirchner J, Roengvoraphoj O, K\u00e4smann L, et al. PET\/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions. Eur J Nucl Med Mol Imaging. 2021;48:3975\u201389. https:\/\/doi.org\/10.1007\/s00259-021-05211-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7326_CR14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.copbio.2011.06.009","volume":"22","author":"I Vaneycken","year":"2011","unstructured":"Vaneycken I, D\u2019Huyvetter M, Hernot S, De Vos J, Xavier C, Devoogdt N, et al. Immuno-imaging using nanobodies. Curr Opin Biotechnol. 2011;22:877\u201381. https:\/\/doi.org\/10.1016\/j.copbio.2011.06.009.","journal-title":"Curr Opin Biotechnol"},{"key":"7326_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1007\/s11307-010-0428-4","volume":"13","author":"LO Gainkam","year":"2011","unstructured":"Gainkam LO, Keyaerts M, Caveliers V, Devoogdt N, Vanhove C, Van Grunsven L, et al. Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy. Mol Imaging Biol. 2011;13:940\u20138. https:\/\/doi.org\/10.1007\/s11307-010-0428-4.","journal-title":"Mol Imaging Biol"},{"key":"7326_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.apradiso.2013.01.039","volume":"76","author":"SR Banerjee","year":"2013","unstructured":"Banerjee SR, Pomper MG. Clinical applications of Gallium-68. Appl Radiat Isot. 2013;76:2\u201313. https:\/\/doi.org\/10.1016\/j.apradiso.2013.01.039.","journal-title":"Appl Radiat Isot"},{"key":"7326_CR17","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.2967\/jnumed.124.268751","volume":"65","author":"W Huang","year":"2024","unstructured":"Huang W, Cao M, Wu Y, Zhang Y, An S, Pan X, et al. Immuno-PET\/CT imaging of Trop2 with [(18)F]AlF-RESCA-T4 differentiates lung Cancer from inflammation. J Nucl Med. 2024;65:1904\u201310. https:\/\/doi.org\/10.2967\/jnumed.124.268751.","journal-title":"J Nucl Med"},{"key":"7326_CR18","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.7150\/thno.98178","volume":"14","author":"X Liu","year":"2024","unstructured":"Liu X, Ma L, Li J, Sun L, Yang Y, Liu T, et al. Trop2-targeted therapies in solid tumors: advances and future directions. Theranostics. 2024;14:3674\u201392. https:\/\/doi.org\/10.7150\/thno.98178.","journal-title":"Theranostics"},{"key":"7326_CR19","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s13244-010-0062-3","volume":"2","author":"NM Long","year":"2011","unstructured":"Long NM, Smith CS. Causes and imaging features of false positives and false negatives on F-PET\/CT in oncologic imaging. Insights into Imaging. 2011;2:679\u201398. https:\/\/doi.org\/10.1007\/s13244-010-0062-3.","journal-title":"Insights into Imaging"},{"key":"7326_CR20","doi-asserted-by":"publisher","unstructured":"Chen H, Zhao L, Pang Y, Shi J, Gao H, Sun Y, et al. 68Ga-MY6349 PET\/CT imaging to assess Trop2 expression in multiple types of cancer. J Clin Invest. 2024;135. https:\/\/doi.org\/10.1172\/jci185408.","DOI":"10.1172\/jci185408"},{"key":"7326_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7326_CR22","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00259-021-05563-1","volume":"49","author":"W Chen","year":"2022","unstructured":"Chen W, Li M, Younis MH, Barnhart TE, Jiang D, Sun T, et al. ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49:861\u201370. https:\/\/doi.org\/10.1007\/s00259-021-05563-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7326_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00259-022-05954-y","volume":"50","author":"C Li","year":"2022","unstructured":"Li C, Liu J, Yang X, Yang Q, Huang W, Zhang M, et al. Theranostic application of (64)Cu\/(177)Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models. Eur J Nucl Med Mol Imaging. 2022;50:168\u201383. https:\/\/doi.org\/10.1007\/s00259-022-05954-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7326_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/j.semnuclmed.2015.03.004","volume":"45","author":"P Flechsig","year":"2015","unstructured":"Flechsig P, Mehndiratta A, Haberkorn U, Kratochwil C, Giesel FL. PET\/MRI and PET\/CT in lung lesions and thoracic malignancies. Semin Nucl Med. 2015;45:268\u201381. https:\/\/doi.org\/10.1053\/j.semnuclmed.2015.03.004.","journal-title":"Semin Nucl Med"},{"key":"7326_CR25","doi-asserted-by":"publisher","unstructured":"Jiang Y, Zhou H, Liu J, Ha W, Xia X, Li J, et al. Progress and innovative combination therapies in Trop-2-Targeted ADCs. Pharmaceuticals (Basel). 2024;17. https:\/\/doi.org\/10.3390\/ph17050652.","DOI":"10.3390\/ph17050652"},{"key":"7326_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/genesandcancer.40","volume":"6","author":"A Shvartsur","year":"2015","unstructured":"Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications. Genes Cancer. 2015;6:84\u2013105. https:\/\/doi.org\/10.18632\/genesandcancer.40.","journal-title":"Genes Cancer"},{"key":"7326_CR27","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","volume":"99","author":"D Fong","year":"2008","unstructured":"Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99:1290\u20135. https:\/\/doi.org\/10.1038\/sj.bjc.6604677.","journal-title":"Br J Cancer"},{"key":"7326_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1476-4598-9-253","volume":"9","author":"R Cubas","year":"2010","unstructured":"Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010;9:253. https:\/\/doi.org\/10.1186\/1476-4598-9-253.","journal-title":"Mol Cancer"},{"key":"7326_CR29","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/s0140-6736(23)01245-x","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cort\u00e9s J, Schmid P, Loirat D, et al. Overall survival with sacituzumab Govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423\u201333. https:\/\/doi.org\/10.1016\/s0140-6736(23)01245-x.","journal-title":"Lancet"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07326-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07326-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07326-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T08:36:36Z","timestamp":1759394196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07326-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7326"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07326-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were performed in accordance with the ethics standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethics standards. Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}